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Introduction 
and epidemiology
Squamous cell carcinoma of the 
conjunctiva is the end-stage of a 
spectrum of disease referred to as ocular 
surface squamous neoplasia (OSSN). 
OSSN is a malignant disease of the eyes 
that can lead to loss of vision and, in 
severe cases, death. The main risk factors 
for both are exposure to solar ultraviolet 
radiation outdoors, HIV/AIDS, human 
papilloma virus and allergic conjunctivitis. 
The limbal epithelial cells appear to be the 
progenitorsof this disease. 
OSSN is an important ophthalmic 
public health problem in equatorial 
Africa, where there are both high levels 
of UV radiation and a high incidence of 
HIV/AIDS. Africa has the highest incidence 
of OSSN in the world, affecting about 
1.3 people per 100,000 population per 
year; so, if you work in an eye clinic 
serving a population of 1 million people, 
you could expect to see one case each 
month if they all came to the clinic.1 
By contrast, the incidence in other 
regions is about 0.1 people per 100,000 
population per year, over 10 times lower.
Two disease patterns occur. In 
equatorial Africa, OSSN affects younger 
adults and proportionally more women 
than in other parts of the world. Recent 
studies in Kenya, for example, found that 
the mean age of OSSN patients is around 
40 years, two-thirds are women and 
about three-quarters are living with HIV. 
Elsewhere, OSSN affects older adults (the 
mean age is about 60 years) and 70% 
are male.
Clinical presentation
This disease has a variable appearance 
(Figure 1). Red eye, photophobia, 
irritation, foreign body sensation and 
a white, painless, progressive growth 
on the surface of the eye are common 
presenting symptoms.2 Most lesions 
occur in the interpalpebral fissure, 
especially on the nasal side.3 They involve 
the conjunctiva and may extend onto 
the peripheral cornea, so visual acuity is 
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often normal in the early stages. It usually 
only involves one eye. The surface may 
be gelatinous, papillomatous or fibro-
vascular. There is usually inflammation, 
leukoplakia and markedly dilated blood 
vessels, referred to as feeder vessels. 
Some brown to black pigmentation of the 
lesion is common in African population 
groups. Most lesions are about 7 mm 
wide at presentation but late presen-
tation with large orbital tumours are not 
uncommon.
Diagnosis
Most cases are diagnosed from the 
clinical impression. There is a shortage 
of histopathology services in most 
equatorial countries; however, even in 
countries without this limitation, about 
half of the lesions are not excised for 
histopathology. This may be related 
to the increasing trend to treat these 
lesions with primary topical medication. 
However, the clinical impression is 
unreliable, especially in equatorial Africa, 
as both benign and malignant lesions 
have overlapping features. There is also 
the ethical consideration of using poten-
tially dangerous topical medications, 
such as cytotoxic drugs, without a tissue 
diagnosis.
Histopathology is the gold standard 
for diagnosis: the pathologist will see an 
abrupt transition between the normal 
and abnormal tissues. However, histo-
pathology is not without challenges. It 
requires surgical intervention for excision 
and the interpretation is subjective, 
varying between pathologists. It is particu-
larly challenging in the earlier stages of 
OSSN, when it is pre-cancerous. After 
excision, the specimen often rolls up 
if immediately put in formalin, making 
orientation difficult. This can be counter-
acted by first placing the specimen on 
sterile suture packing foam for a few 
minutes to stiffen before putting it in 
formalin. Fragmentation of small tumour 
specimens and shearing of the surface 
layers may occur during processing, 
making the judgement of depth of 
involvement difficult.
Although vital staining with topical 
toluidine blue 0.05% stains most lesions 
dark royal blue with a high sensitivity, the 
specificity is low due to false positives in 
benign lesions (Figure 2).4 
Treatment
Surgical excision under the microscope 
is the most commonly used technique. 
Small lesions are simply excised in total 
while larger ones involving the orbit may 
need exenteration, a radical technique 
that involves removing all the orbital 

































Small lesion with leukoplakia Medium-sized lesion with pigmentation
Large lesion with corneal extension but 
not involving the fornices
Very large lesion extending into the 
orbit
Figure 1. A range of OSSN presentations seen in East Africa.1 
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Lesions are excised with a 4 mm margin, 
dissecting down to the sclera without 
touching the tumour. Some surgeons 
use the bare sclera technique which 
allows the conjunctiva to re-epithelialise, 
whereas others mobilise the surrounding 
conjunctiva for primary closure of 
the defect and earlier post-operative 
adjuvant chemotherapy. Other ways of 
closing the defect are by autologous 
conjunctival graft from the other eye or 
by using commercially available amniotic 
membrane. Absolute alcohol is applied 
to the corneal extension of the lesion to 
loosen the tissue from the cornea, so 
that it can be dissected microsurgically 
with a blade. 
Adjuvant therapies to augment 
surgery include cryotherapy, where 
2–4 freeze-thaw cycles are used to oblit-
erate residual tumour at the bed and 
margins. Topical cytotoxic drugs, such as 
5-fluorouracil (5FU) and mitomycin C,
may be applied to the bed for about
2.5 minutes then washed off. Other
agents include interferon alpha 2b
drops, cyclosporin A, all-trans retinoic
acid, anti-VEGF agents and radiotherapy.
Many centres in Africa do not have
cryotherapy or other adjuvants, except
for 5FU, which is frequently available.
Topical antibiotic-steroid combination
eyedrops are applied 4 times daily for
about 3–4 weeks after the primary
excision, until the site heals.
Recurrence after the primary excision 
can be frequent. Surgical excision 
alone is associated with recurrences 
of 3.2% to 67% at an average of 32 
months. HIV testing and treatment 
should be considered standard practice 
for all patients presenting with OSSN. 
We recently conducted a randomised 

















Figure 3. Picture A shows the pre-operative appearance of a lesion in a 32-year-old 
woman. She was HIV infected with a CD4 count of 69 cells/µL. The lesion was excised 
with a 4 mm margin. She was given topical Gentamycin and Prednisolone drops 4 times 
daily for 3 weeks. Histopathology showed moderately differentiated squamous cell 
carcinoma. She was given 1% 5FU drops to apply 4 times daily for 4 weeks. 

































Figure 2. Conjunctival lesions before and after staining with 0.05% toluidine blue. 
The pictures in the left column are before staining and those on the right after 
staining. Images A and B show moderately differentiated squamous cell carcinoma, 
with deep royal blue staining. C and D show actinic keratosis, with mixed staining 
(margin and parts of the lesion).
drops applied 4 times daily after the 
excision site healed (usually 2–3 weeks 
after excision) for OSSN lesions <2 
quadrants in diameter.5 It decreased the 
risk of recurrence one year after excision 
from 36% to 11%.There were transient 
adverse effects such as a watery eye, 
discomfort when applying the drops and 
eyelid inflammation, which settled within 
2–3 weeks after completion of treatment. 
In Kenya the estimated cost of a 4-week 
treatment course of 5FU eyedrops is 320 
Kenyan shillings (US $3.20). 
Follow-up
Follow-up is important to monitor for 
recurrence, including everting the upper 
eyelid in case of recurrent tumour on 
the tarsal conjunctiva. Most recurrences 
in sub-Saharan Africa present early (3 
and 6 months later). Reviews in this 
region should ideally be done 1, 3 and 
6 months after surgery. After one year, 
reviews may be conducted at month 18, 
24 and 36 after surgery. For large lesions 
that need more radical surgery, the 
follow-up regimes vary. Some surgeons 
use radiotherapy after surgery.
Patient counselling
There is no word for OSSN in most local 
languages. Calm reassurance is needed, 
especially as this cancer tends not to 
metastasise and in the majority of cases 
is not life threatening. Most patients 
will be anxious when told that they have 
cancer in their eye. In those living with 
HIV, this may be compounded by other 
concerns related to the complications of 
HIV. For people with large orbital tumours 
there may be fear of general anaesthesia. 
The possibility of recurrence and the need 
to follow up in the clinic is essential. 
It is helpful to give patients evidence 
of the success of surgical excision with 
adjuvant therapy (for smaller lesions). 
For example, former patients who are 
willing to share their experiences with 
other patients can be very helpful ‘change 
agents,’ and can reassure and encourage 
others to come for treatment. 
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